没药对人乳腺癌MDA-MB-231细胞糖酵解及增殖的影响

Effect of myrrha on glycolysis and proliferation in human breast cancer MDA-MB-231 cells

摘要

目的 探讨没药对人乳腺癌细胞MDA-MB-231的糖酵解水平和细胞增殖的影响。方法 不同浓度没药处理乳腺癌细胞24 h后，采用细胞计数法（CCK-8）检测没药对乳腺癌细胞增殖活性的影响，Annexin V-FITC/PI双染流式细胞实验检测没药对乳腺癌细胞凋亡的影响，比色法检测没药对乳腺癌细胞乳酸生成和葡萄糖消耗的影响，蛋白免疫印迹法（WB）检测没药对乳腺癌细胞6磷酸果糖2激酶/果糖-2,6二磷酸酶3（PFKFB3）、葡萄糖转运体1（GLUT1）、乳酸脱氢酶A（LDHA）、丙酮酸脱氢酶激酶1（PDHK1）蛋白表达情况。结果 没药可降低PFKFB3、GLUT1、LDHA、PDHK1蛋白表达（P<0.05），降低葡萄糖消耗和乳酸生成，从而降低乳腺癌细胞MDA-MB-231糖酵解水平，抑制细胞增殖，促进乳腺癌细胞凋亡（P<0.05）。结论 没药通过降低PFKFB3、GLUT1、LDHA、PDHK1蛋白表达，降低糖酵解水平，抑制乳腺癌细胞增殖。

Abstract

Objective To study the effects of myrrha on the proliferation and glycolysis in breast cancer cells MDA-MB-231. Methods The effect of the myrrha on proliferation activity of the cells was detected by CCK-8, and Annexin V-FITC/PI double staining flow cytometry was used to detect the effect of myrrha on apoptosis of breast cancer cells. Glucose and lactate were detected by colorimetry, and the expression levels of 6-Phosphofructo-2-kiase/fructose-2,6-biphosphatase 3 (PFKFB3), glucose transporter 1 (GLUT1), pyruvate dehydrogenase kinase 1 (PDHK), lactate dehydrogenase A (LDHA) proteins were verified by Western blot. Results Myrrha effectively reduced the level of PFKFB3, GLUT1, LDHA, and PDHK1 protein (P<0.05), and decreased glucose consumption and lactate production, thus down-regulating glycolysis level, inhibiting cell proliferation and promoting apoptosis. Conclusion Myrrha can reduce the expression of PFKFB3, GLUT1, LDHA, and PDHK1 proteins, thereby lowering glycolytic levels and inhibiting the proliferation of breast cancer cells.

关键词

乳腺癌 / 没药 / 糖酵解 / 增殖

Key words

breast cancer / myrrha / glycolysis / proliferation

参考文献

[1] Han B F, Zheng R S, Zeng H M, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53.

[2] 杨宝, 徐莲莲, 陈芳有, 等. 没药化学成分及抗炎活性研究[J]. 中草药, 2023, 54(9): 2716-2721.

[3] 周海燕, 杜杰, 白杨, 等. 经典名方中没药的本草考证[J]. 中国实验方剂学杂志, 2022, 28(10): 123-129.

[4] Galindo C M, Oliveira Ganzella F A, Klassen G, et al. Nuances of PFKFB3 signaling in breast cancer[J]. Clin Breast Cancer, 2022, 22(4): 604-614.

[5] Zhang S, Wang X, Zhang R, et al. A GLUT1 inhibitor-based fluorogenic probe for Warburg effect-targeted drug screening and diagnostic imaging of hyperglycolytic cancers[J]. Anal Chim Acta, 2021, 1167(6): 338593.

[6] Pan B S, Hsu C C, Wu H E, et al. Glucose metabolism and its direct action in cancer and immune regulation: opportunities and challenges for metabolic targeting[J]. J Biomed Sci, 2025, 32(1): 71.

[7] Varma G, Seth P, Coutinho De Souza P, et al. Visualizing the effects of lactate dehydrogenase (LDH) inhibition and LDH-A genetic ablation in breast and lung cancer with hyperpolarized pyruvate NMR[J]. NMR Biomed, 2021, 34(8): 4560-4571.

[8] 杨雨婷, 曾瑾, 陈平, 等. 西黄丸抗肿瘤临床应用及药理作用机制研究进展[J]. 中国实验方剂学杂志, 2022, 28(3): 250-258.

[9] 李梦宜, 张磊, 王立军, 等. 西黄丸/胶囊辅助放疗和(或)化疗治疗消化道恶性肿瘤有效性和安全性的Meta分析[J]. 中医杂志, 2025, 66(9): 912-919.

[10] 申国园, 张春泽. 西黄丸调控肿瘤相关信号通路的分子机制研究进展[J]. 中国中西医结合外科杂志, 2026, 32(2): 290-294.

[11] 郑明瑜, 王洋, 彭友飞, 等. 经典名方西黄丸抑制小鼠乳腺癌细胞肺转移的转录组学分析[J/OL]. 中华中医药学刊, 2026, 1-9. https://link.cnki.net/urlid/21.1546.R.20260325.1617.012.

[12] 龚婕, 周瑶, 邓显光, 等. “乳香-没药”药对对乳腺增生大鼠乳腺组织Cyclin D1、Cyclin D2、ERα表达的影响[J]. 时珍国医国药, 2024, 35(6): 1352-1356.

[13] 刘东晓, 刘亚鑫, 黄惠铭, 等. 没药倍半萜化合物M36抑制人肝癌细胞生长的作用[J]. 中国实验方剂学杂志, 2024, 30(5): 80-87.

[14] 夏黄帅, 余卓伦, 张其海, 等. 没药甾酮下调PXR/P-gp通路逆转肝癌化疗耐药机制[J]. 中国药理学通报, 2022, 38(5): 684-691.

[15] 余卓伦, 张其海, 樊昊雯, 等. 没药甾酮通过调控mTOR/自噬通路增强替莫唑胺抗脑胶质瘤的作用研究[J]. 中药材, 2023, 46(2): 462-468.

[16] 姜继军, 高宁. CircRNA调控肿瘤代谢重编程的研究进展[J]. 遵义医科大学学报, 2026, 49(4): 444-455.

[17] Dai C Y, Wang L H. Glycolysis enzymes and cellular lactylation in tumour[J]. Clin Transl Med, 2026, 16(2): e70549.

基金资助

贵州省科技计划项目(黔科合基础-ZK(2023)一般511)

遵义医科大学博士科研启动基金资助项目(F-ZH-008)

遵义医科大学珠海校区大创项目(ZHCX2022064)